Cue Biopharma (CUE) vs Grace Therapeutics (GRCE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Grace Therapeutics (GRCE) has outperformed Cue Biopharma (CUE) over the past year, losing 46.4% versus a loss of 76.8%. Over five years, GRCE leads with a -79.3% price change compared with -98.9% for CUE. Grace Therapeutics is the larger company by market cap ($36.0 million vs $34.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | GRCE |
|---|---|---|
| Share price | $4.15 | $1.71 |
| Market cap | $34.69M | $35.97M |
| 1-day change | -7.78% | -0.58% |
| YTD return | -54.64% | -50.58% |
| 1-year return | -76.75% | -46.39% |
| 5-year return | -98.92% | -79.35% |
| EPS (TTM) | $-27.80 | $-1.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.47M | — |
| Revenue growth (YoY) | +195.75% | — |
| Net income (latest FY) | $-26.60M | $-7.79M |
| Operating margin | -96.67% | — |
| Net margin | -96.85% | — |
| 52-week high | $45.50 | $5.18 |
| 52-week low | $2.83 | $1.64 |
| Distance from 52-week high | -90.88% | -66.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +2020.48% | +243.27% |
| Average volume | 567.02K | 119.27K |
| Shares outstanding | 8.36M | 21.04M |
| Employees | 29 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRCE has outperformed CUE by 30.4 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Grace Therapeutics
GRCE stock →Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CUE vs GRCE FAQ
Which is bigger, Cue Biopharma or Grace Therapeutics?
Grace Therapeutics (GRCE) is larger, with a market capitalization of $35.97M compared with $34.69M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or GRCE?
GRCE returned -46.39% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Grace Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.